COVID-19-associated Cryptococcus infection (CACI): a review of literature and clinical pearlsBrief Report Published on 2022-03-242023-06-18 Journal: Infection [Category] MERS, [키워드] COVID-19 Cryptococcus fungus immunosuppressive opportunistic Infections [DOI] 10.1007/s15010-022-01805-y PMC 바로가기 [Article Type] Brief Report
Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination증례 보고서: ChAdOx1 nCoV-19 백신 접종 후 심각한 횡문근 융해증 및 다기관 부전Case Reports Published on 2022-03-172022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] accelerated Anakinra assumption biologic Bone marrow Case report ChAdOx1 ChAdOx1 nCoV-19 characterized creatine phosphokinase cytokine Cytokine storm Deterioration dramatic increase drug eculizumab failure first dose had no healthy hypoglycemia immunosuppressive Infection inflammatory markers kidney liver lung multi organ failure nine occur occurred patient death patients with SARS-CoV-2 PCT physician procalcitonin rapid increase reported resulting rhabdomyolysis Risk factors SARS-CoV-2 SARS-CoV2 Shock Skeletal muscle Steroids therapy Treatment vaccination vaccine administration [DOI] 10.3389/fimmu.2022.845496 PMC 바로가기 [Article Type] Case Reports
An inhibitor of leukotriene-A4 hydrolase from bat salivary glands facilitates virus infectionArticle Published on 2022-03-082023-06-23 Journal: Proceedings of the National Academy of Sciences of [Category] 신종인플루엔자, [키워드] immunosuppressive Myotis pilosus salivary gland toxin virus transmission [DOI] 10.1073/pnas.2110647119 PMC 바로가기
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?신장 이식 수용자의 늦은 항체-매개 거부 : Covid 19가 유도 되었습니까?Case Reports Published on 2022-03-052022-09-01 Journal: BMC Nephrology [Category] MERS, 진단, [키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody mediated rejection antibody-dependent cell-mediated cytotoxicity antigens association Case report Cell-mediated cytotoxicity connection coronavirus coronavirus disease COVID 19 COVID-19 COVID-19 infection cytomegalovirus cytotoxicity de novo described Donor explain immunological immunosuppressive immunosuppressive therapy Infection kidney transplant kidney transplant recipients KIR2DS1 lowering MONITOR Natural killers NK cells Patient positive presenting rejection reported respiratory risk severe acute respiratory syndrome Coronavirus therapy Transplant Viral viral infections [DOI] 10.1186/s12882-022-02713-x PMC 바로가기 [Article Type] Case Reports
Impact of novel microbial secondary metabolites on the pharma industry제약 산업에 대한 새로운 미생물 2차 대사 산물의 영향Review Published on 2022-03-012022-09-11 Journal: Applied Microbiology and Biotechnology [Category] COVID19(2023년), SARS, 변종, [키워드] Alexander Fleming Antibiotic resistance Antibiotics anticancer anticancer drugs Bacteria caused Clinical practice develop Diseases drug drugs effort function fungi generate Genome Health Hypocholesterolemics immunosuppressants immunosuppressive Impact IMPROVE Infection Infectious disease Infectious diseases introduced Laboratory market metagenomics microbial Microbial natural products. microorganism microorganisms New novel offer overcome pandemic penicillin problems SARS-CoV-2 SARS-CoV-2 pandemic second second wave Secondary Metabolite significantly Smaller the SARS-CoV-2 therapeutic therapy treat Treatment variants viruses Well-being [DOI] 10.1007/s00253-022-11821-5 PMC 바로가기 [Article Type] Review
Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients면역 억제 환자에서 SARS-CoV-2 백신 접종에 대한 세포 및 체액 반응Article Published on 2022-03-012022-09-11 Journal: Cellular immunology [Category] SARS, 치료기술, [키워드] Activation anti-spike antibodies B-cell BNT162b2 BNT162b2 mRNA CD8 ChAdOx1 ChAdOx1 nCoV-19 cohorts comparable COVID-19 cytokine Cytokines demonstrated depleting detectable difference Efficacy elicited haematological malignancies haematological malignancy healthy healthy volunteers highest Humoral response humoral responses immunodominance immunogenic immunological responses Immunophenotyping Immunosuppressed immunosuppressed patient immunosuppressed patients Immunosuppression immunosuppressive immunosuppressive therapy less Longevity Lower memory naïve no significant differences non-responder participant Participants Patient patients treated phenotype preserved protective immunity receiving renal responders response SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines seroconvert serological seropositive Seropositivity significant difference T-cell T-cell ELISpot T-cell Response T-cell responses Th1 cytokine therapy Transplant Vaccinations vaccine immunogenicity vaccine response vaccine responses were used [DOI] 10.1016/j.cellimm.2022.104501 PMC 바로가기 [Article Type] Article
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment항-CD20 단일클론항체는 치료 후 6개월 이내에 비호지킨 림프종 환자에서 Covid-19 예방접종에 대한 혈청양성 반응을 억제합니다Article Published on 2022-03-012022-09-12 Journal: Experimental hematology [Category] MERS, SARS, 진단, 치료법, [키워드] anti-CD20 anti-CD20 treatment B cell caused CD19 death Efficacy immunosuppressive indicated inhibit less lymphocyte lymphoma monoclonal antibodies monoclonal antibody Non-Hodgkin Lymphoma pandemic Patient Pfizer-BioNTech Prevent respond seropositive the healthy the vaccine therapy treated Treatment vaccination Vaccine volunteers [DOI] 10.1016/j.exphem.2021.12.396 PMC 바로가기 [Article Type] Article
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trialClinical Trial Published on 2022-03-012022-10-05 Journal: Vaccine [Category] SARS, 임상, [키워드] AEs baseline BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Cancer clinical clinical trials COVID-19 COVID-19 pandemic COVID-19 vaccine death Efficacy Efficacy and safety excluded fatigue Follow-up follow-up time high risk Hospitalization immunosuppressive incidence rate individual Infection Injection-site pain malignancy Melanoma MOST neoplasm Neoplasms observer-blinded outcomes participant Participants Phase 3 Placebo placebo recipient placebo-controlled Prostate Pyrexia Randomized randomized clinical trial reactogenicity event receiving reported Safe Safety subgroup analysis therapy Trial unblinding Vaccine were excluded [DOI] 10.1016/j.vaccine.2021.12.046 PMC 바로가기 [Article Type] Clinical Trial
Modulation of Covid-19 cytokine storm by tocilizumab토실리주맙에 의한 Covid-19 사이토카인 폭풍의 조절Article Published on 2022-03-012022-09-12 Journal: Journal of medical virology [Category] SARS, 진단, [키워드] acute respiratory syndrome addition antivirals appear caused Clinical studies component coronavirus Coronavirus disease 2019 COVID-19 Cytokine storm determine Fatality rate global pandemic Health IL-1 IL-6 immunosuppressive Immunosuppressive agents include Infection inhibitor interleukin Inhibitors majority organizations Prevent reported Severe case standard treatment the cytokine storm therapeutic approaches Tocilizumab Treatment World Health Organization Wuhan, China [DOI] 10.1002/jmv.27380 PMC 바로가기 [Article Type] Article
T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease염증성 장 질환이 있는 면역 저하 환자에서 SARS-CoV-2 백신 접종 후 T 세포 반응Article Published on 2022-02-232022-09-11 Journal: Journal of Crohn's & colitis [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] absence age analysed anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody titres blood sample Blood samples Cell cellular cellular and humoral immune response Cellular immune response cellular immunity close monitoring comparable Control controls COVID19 Cutoff detect dose of vaccination Efficacy first dose group healthy healthy control healthy controls humoral immune response IBD IFN-γ immune response immune responses Immunity Immunocompromised Immunosuppression immunosuppressive infection with SARS-CoV-2 Inflammatory bowel disease one patient Patient patients PROTECT recruited regimens response SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 vaccination second dose slight increase T cell T cell response Th cells TNF TNF-α Total university vaccination [DOI] 10.1093/ecco-jcc/jjab147 PMC 바로가기 [Article Type] Article